This website is a global resource for healthcare professionals (HCP) only.
This website is produced by Roche and is not intended to provide medical advice and/or treatment guidance. This website is not country specific and therefore may contain information that is not applicable to your country.
Please click the “I am an HCP” button if you belong to this group.
If you are not a healthcare professional or researcher but would like to learn more about WAYFIND-R, please click the “I am not an HCP” button below to be redirected to our patient website, which provides information on the trials conducted by Roche.
WAYFIND-R is a global registry that will collect data from patients who have been diagnosed with a solid tumour and whose tumour has been profiled with a next-generation sequencing (NGS) test.
WAYFIND-R aims to enable collaborations and to provide meaningful insights and high-quality evidence to enhance our understanding of precision oncology and ultimately transform the lives of people with cancer.
WAYFIND-R is a global, multicentre, prospective pan-cancer registry to collect long-term data to gain clinical insights on characteristics and outcomes from patients with solid tumors profiled with a next-generation sequencing (NGS) test in routine care.
WAYFIND-R aims to provide the medical and scientific community with access to high-quality data and exciting opportunities to collaborate and help advance cancer research, all within a secure database.
WAYFIND-R is always looking to expand its community and work with new sites. The more sites that join, the more representative the WAYFIND-R population becomes. This will improve the quality and relevance of WAYFIND-R’s data and, in addition, its research capabilities and value for patients.
5504
participants
32
participating
countries
*Note that the estimated numbers are subject to change (status as of 7/Apr/2025).
WAYFIND-R active sites map